The European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) International Meeting 2018, the first of its kind, was held in Barcelona, Spain, from 25–27 October.

Explore the latest CLL news with meeting highlights from the speakers themselves, including biomarkers, opinion on MRD, epigenetics and data to watch out for at ASH 2018.

ERIC 2018

ERIC 2018

The European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) International Meeting 2018, the first of its kind, was held in Barcelona, Spain, from 25–27 October.

Explore the latest CLL news with meeting highlights from the speakers themselves, including biomarkers, opinion on MRD, epigenetics and data to watch out for at ASH 2018.

Projections from real world evidence of CLL management 4:20
Projections from real world evidence of CLL management
Robin Foà • 25 Oct 2018
Treatment-changing advancements in CLL: BTK, BCL-2, CD20 & CAR T-cells 9:35
Treatment-changing advancements in CLL: BTK, BCL-2, CD20 & CAR T-cells
Kanti Rai • 25 Oct 2018
Genomic discoveries in CLL 2:49
Genomic discoveries in CLL
Richard Rosenquist • 25 Oct 2018
Opinion on MRD in CLL: routine use or clinical trials? 3:18
Opinion on MRD in CLL: routine use or clinical trials?
Kanti Rai • 25 Oct 2018
Resistance mechanisms in CLL 3:08
Resistance mechanisms in CLL
Richard Rosenquist • 25 Oct 2018
ERIC’s first International Meeting and plans for the future 1:52
ERIC’s first International Meeting and plans for the future
Paolo Ghia • 25 Oct 2017
Current ERIC research in the CLL genomics field 1:50
Current ERIC research in the CLL genomics field
Richard Rosenquist • 25 Oct 2018
Progress in CLL diagnosis and treatment 1:37
Progress in CLL diagnosis and treatment
Kanti Rai • 25 Oct 2018
European Research Initiative on CLL (ERIC) International Meetings 1:00
European Research Initiative on CLL (ERIC) International Meetings
Kostas Stamatopoulos • 25 Oct 2018
CLL cell dynamics 2:13
CLL cell dynamics
Nicholas Chiorazzi • 25 Oct 2018
An update on ERIC initiatives 0:51
An update on ERIC initiatives
Paolo Ghia • 25 Oct 2018
CLL treatment duration and the role of MRD 1:44
CLL treatment duration and the role of MRD
Peter Hillmen • 25 Oct 2018
Prognostic markers and MRD in CLL 6:28
Prognostic markers and MRD in CLL
Robin Foà • 25 Oct 2018
Current knowledge of the TP53 mutation and its role in CLL 2:36
Current knowledge of the TP53 mutation and its role in CLL
Jitka Malčíková • 25 Oct 2018
Cell-extrinsic biomarkers for CLL: immunogenetic data 1:20
Cell-extrinsic biomarkers for CLL: immunogenetic data
Andreas Agathangelidis • 25 Oct 2018
Cell-intrinsic biomarkers in CLL: focus on cytogenetics 3:01
Cell-intrinsic biomarkers in CLL: focus on cytogenetics
Blanca Espinet • 25 Oct 2018
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals